Dileep Bhagwat
Keine laufenden Positionen mehr
Profil
Dileep Bhagwat worked as an Assistant Director of Pharmaceutical Development at The Purdue Frederick Research Center from 1994 to 1999.
He then worked as the CSO and Vice President of Research & Development at Bradley Pharmaceuticals, Inc. from 1999 to 2009.
From 1994 to 1999, he was the VP of Scientific Development & Regulatory Affairs at Penwest Pharmaceuticals Co. Bhagwat also worked as the Senior Vice President of Pharmaceutical Development at EpiCept Corp.
from 2011 to 2012.
Bhagwat holds an MBA from Pace University, a graduate and doctorate degree from St. John's University, and an undergraduate degree from the University of Mumbai.
Ehemalige bekannte Positionen von Dileep Bhagwat
Unternehmen | Position | Ende |
---|---|---|
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Corporate Officer/Principal | 15.12.2012 |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.1999 |
The Purdue Frederick Research Center | Corporate Officer/Principal | 01.09.1999 |
Bradley Pharmaceuticals, Inc.
Bradley Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Bradley Pharmaceuticals, Inc. is a specialty pharmaceutical company, engages in the acquisition, development and marketing of prescription and products to physician specialties in the United States and international markets. The company has two divisions: Doak Dermatologics and Kenwood Therapeutics. The Doak Dermatologics division promotes branded dermatologic and podiatric products including ADOXA, KERALAC, SOLARAZE, ZODERM, LIDAMANTLE, ROSULA, SELSEB and ZONALON to dermatologists and podiatrists. The Kenwood Therapeutics division offers branded gastrointestinal products including ANAMANTLE HC, PAMINE and PAMINE FORTE to gastroenterologists, colon and rectal surgeons. It also markets nutritional supplements and respiratory products including FLORA-Q. The company’s products are used in the treatment of acne, mild to severe dry skin and nail disorders, actinic keratoses, precancerous skin lesions, topical anesthetic and anti-inflammatory diseases, dandruff, hemorrhoids and anal fissures. It markets and sells it's products through sales personnel and wholesalers. The company was founded by Daniel Glassman in 1985 and is headquartered in Fairfield, NJ. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Dileep Bhagwat
Pace University | Masters Business Admin |
St. John's University | Doctorate Degree |
University of Mumbai | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Bradley Pharmaceuticals, Inc.
Bradley Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Bradley Pharmaceuticals, Inc. is a specialty pharmaceutical company, engages in the acquisition, development and marketing of prescription and products to physician specialties in the United States and international markets. The company has two divisions: Doak Dermatologics and Kenwood Therapeutics. The Doak Dermatologics division promotes branded dermatologic and podiatric products including ADOXA, KERALAC, SOLARAZE, ZODERM, LIDAMANTLE, ROSULA, SELSEB and ZONALON to dermatologists and podiatrists. The Kenwood Therapeutics division offers branded gastrointestinal products including ANAMANTLE HC, PAMINE and PAMINE FORTE to gastroenterologists, colon and rectal surgeons. It also markets nutritional supplements and respiratory products including FLORA-Q. The company’s products are used in the treatment of acne, mild to severe dry skin and nail disorders, actinic keratoses, precancerous skin lesions, topical anesthetic and anti-inflammatory diseases, dandruff, hemorrhoids and anal fissures. It markets and sells it's products through sales personnel and wholesalers. The company was founded by Daniel Glassman in 1985 and is headquartered in Fairfield, NJ. | Health Technology |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | Health Technology |
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Health Technology |
The Purdue Frederick Research Center |